Asceneuron SA has appointed J Michael Ryan as chief medical officer to lead development of its portfolio of small molecules for neurodegenerative diseases. A former Novartis executive, Dr Ryan managed programmes for the Swiss company in a number of central nervous system indications including Alzheimer’s and Parkinson’s diseases and schizophrenia. He has also held senior positions at Pfizer, Wyeth Research, and MSD Research Laboratories.
Dr Ryan received a medical degree from the Medical University of South Carolina and a Bachelor of Science in biology from Georgetown University.
Asceneuron announced the appointment on 6 December 2016.
Copyright 2016 Evernow Publishing Ltd